EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Efavirenz, Emtricitabine, And Tenofovir Disoproxil Fumarate, and when can generic versions of Efavirenz, Emtricitabine, And Tenofovir Disoproxil Fumarate launch?
Efavirenz, Emtricitabine, And Tenofovir Disoproxil Fumarate is a drug marketed by Aurobindo Pharma, Cipla, Hetero Labs Ltd V, Laurus, Macleods Pharms Ltd, and Teva Pharms Usa. and is included in six NDAs.
The generic ingredient in EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE is efavirenz; emtricitabine; tenofovir disoproxil fumarate. There are twenty-six drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the efavirenz; emtricitabine; tenofovir disoproxil fumarate profile page.
Summary for EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE
US Patents: | 0 |
Applicants: | 6 |
NDAs: | 6 |
Finished Product Suppliers / Packagers: | 7 |
Raw Ingredient (Bulk) Api Vendors: | 10 |
Clinical Trials: | 39 |
Patent Applications: | 21 |
Formulation / Manufacturing: | see details |
DailyMed Link: | EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE at DailyMed |
Recent Clinical Trials for EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida | N/A |
Yu-Jay Corp. | Phase 3 |
University of Alberta | Phase 4 |
See all EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE clinical trials
Pharmacology for EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE
Anatomical Therapeutic Chemical (ATC) Classes for EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE
US Patents and Regulatory Information for EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aurobindo Pharma | EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE | efavirenz; emtricitabine; tenofovir disoproxil fumarate | TABLET;ORAL | 203041-001 | Sep 4, 2018 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Laurus | EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE | efavirenz; emtricitabine; tenofovir disoproxil fumarate | TABLET;ORAL | 213541-001 | Dec 22, 2021 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Cipla | EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE | efavirenz; emtricitabine; tenofovir disoproxil fumarate | TABLET;ORAL | 206894-001 | Jun 3, 2019 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |